Search Results - "Delarue, R."

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers by Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquières, H., Tournilhac, O., da Silva, M. Gomes, Bouabdallah, R., Salles, G., Bachy, E.

“…Peripheral T-cell lymphoma (PTCL) remains a therapeutic challenge. Due to the rarity and the heterogeneity of PTCL, no consensus has been achieved regarding…”
Get full text

FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study by Casasnovas, R.-O., Ysebaert, L., Thieblemont, C., Bachy, E., Feugier, P., Delmer, A., Tricot, S., Gabarre, J., Andre, M., Fruchart, C., Mounier, N., Delarue, R., Meignan, M., Berriolo-Riedinger, A., Bardet, S., Emile, J.-F., Jais, J.-P., Haioun, C., Tilly, H., Morschhauser, F.

“…Dose-dense induction and up-front consolidation with autologous stem cell transplantation (ASCT) remain controversial issues when treating patients with…”
Get full text

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL) by Cottereau, A.S., Becker, S., Broussais, F., Casasnovas, O., Kanoun, S., Roques, M., Charrier, N., Bertrand, S., Delarue, R., Bonnet, C., Hustinx, R., Gaulard, P., de Leval, L., Vera, P., Itti, E., Mounier, N., Haioun, C., Tilly, H., Meignan, M.

“…Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed. The prognostic impact…”
Get full text

Ulna shortening osteotomy versus arthroscopic wafer procedure in the treatment of ulnocarpal impingement syndrome by Auzias, P., Delarue, R., Camus, E.J., Van Overstraeten, L.

“…Post-traumatic or constitutional ulnar impaction syndrome can be treated by shortening the ulna. This can be achieved by diaphyseal or metaphyseal osteotomy,…”
Get full text

Lymphomas: A therapeutic update by Wolfromm, A, Delarue, R

“…Emergence of new molecules has considerably reshaped the management of patients in onco-hematology. Cytotoxic chemotherapy has not been altered, and CHOP…”
Get full text

Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia by Pouvaret, A., Guery, R., Montillet, M., Molina, T.J., Duréault, A., Bougnoux, M.E., Galliot, R., Lanternier, F., Delarue, R., Lortholary, O.

“…We read with great interest the article from Peri et al. describing a case report of invasive aspergillosis (IA) with primary pulmonary involvement followed by…”
Get full text

Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: Report of 21 cases and review of the literature by Audard, V., Larousserie, F., Grimbert, P., Abtahi, M., Sotto, J-J, Delmer, A., Boue, F., Nochy, D., Brousse, N., Delarue, R., Remy, P., Ronco, P., Sahali, D., Lang, P., Hermine, O.

“…Minimal change nephrotic syndrome (MCNS) is described as a paraneoplastic manifestation of classical Hodgkin's lymphoma (cHL). We reassessed the…”
Get full text

Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’: [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723] by Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquières, H., Tournilhac, O., Gomesda Silva, M., Bouabdallah, R., Salles, G., Bachy, E.

Get full text

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial by Petrella, T., Copie-Bergman, C., Brière, J., Delarue, R., Jardin, F., Ruminy, P., Thieblemont, C., Figeac, M., Canioni, D., Feugier, P., Fabiani, B., Leroy, K., Parrens, M., André, M., Haioun, C., Salles, G.A., Gaulard, P., Tilly, H., Jais, J.P., Molina, T.J.

“…Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk…”
Get full text

Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trial by Trotman, J., Tedeschi, A., Hu, B., Linton, K. M., McKay, P., Leitch, S., Jin, J., Sun, M., Sobieraj‐Teague, M., Zinzani, P. L., Browett, P., Thieblemont, C., Liberati, A. M., Bachy, E., Cavallo, F., Costello, R., Iyengar, S., Marasca, R., Mociková, H., Kim, J. S., Talaulikar, D., Liang, Z., Xu, J., Tankersley, C., Delarue, R., Co, M., Opat, S.

Get full text

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY by Zinzani, P. L., Mayer, J., Trotman, J., Bijou, F., de Oliveira, A. C., Song, Y., Zhang, Q., Merli, M., Bouabdallah, K., Ganly, P. S., Zhang, H., Johnson, R., Garcia‐Sancho, A. M., Pulla, M. Provencio, Trněný, M., Yuen, S., Assouline, S. E., Auer, R., Ivanoa, E., Kim, P., Greenbaum, A., Huang, S., Delarue, R., Flowers, C. R.

Get full text

Distal interphalangeal joint arthrodesis with the intramedullary Lync® implant: Prospective study of 22 cases by Auzias, P., Delarue, R., Strouk, G., Guerre, E., Limousin, M., Fontaine, C., Aumar, A.

“…Several techniques have been described for fusion of the distal interphalangeal joint. The intramedullary Lync® implant (Novastep™) may be superior to other…”
Get full text

ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIAL by Camus, V., Thieblemont, C., Gaulard, P., Cheminant, M., Casasnovas, R., Ysebaert, L., Damaj, G. L., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., Andre, M., Gutiérrez, N., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Rossi, G., Delfau‐Larue, M., Cottereau, A., Itti, E., Li, J., Delarue, R., Leval, L., Morschhauser, F., Bachy, E.

Get full text

LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIAL by Camus, V., Belot, Aurél., Oberic, L., Sibon, D., Ghesquières, H., Thieblemont, C., Fruchart, C., Casasnovas, O., Michot, Jean‐M., Molina, T. J., Bosly, A., Joubert, Clém., Haioun, C., Delarue, R., Tilly, H.

Get full text

THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) by Morschhauser, F., Nowakowski, G. S., Cartron, G., Kesanakurthy, V., Gkasiamis, A., Patah, P., Delarue, R., Wang, T., Li, J., Xian, D., Fox, C. P., Martin, P.

Get full text

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) by Ketterer, N., Coiffier, B., Thieblemont, C., Fermé, C., Brière, J., Casasnovas, O., Bologna, S., Christian, B., Connerotte, T., Récher, C., Bordessoule, D., Fruchart, C., Delarue, R., Bonnet, C., Morschhauser, F., Anglaret, B., Soussain, C., Fabiani, B., Tilly, H., Haioun, C.

“…The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide,…”
Get full text

Investigation and management of patients presenting with thrombocytosis by Cheminant, M, Delarue, R

“…Thrombocytosis is a common finding when performing a blood count. It is often consecutive to an underlying condition and then does not lead to thrombotic…”
Get full text

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL by Zinzani, P. L., Mayer, J., Auer, R., Bijou, F., de Oliveira, A. C., Flowers, C. R., Merli, M., Bouabdallah, K., Ganly, P. S., Song, Y., Zhang, H., Johnson, R., García-Sancho, A. M, Provencio, M., Trněný, M., Yuen, S., Tilly, H., Kingsley, E., Tuyman, G., Assouline, S. E., Ivanova, E., Kim, P., Huang, J., Delarue, R., Trotman, J.

Get full text

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA by Sehn, L., Sarkozy, C., Song, Y., Salar, A., Trotman, J., Zinzani, P. L., Zhang, J., Zhang, W., Fustier, P., Delarue, R., Nastoupil, L.

Get full text

Thalidomide therapy induces response in relapsed mantle cell lymphoma by Damaj, G, Lefrère, F, Delarue, R, Varet, B, Furman, R, Hermine, O

Get full text